A Study of the Effect of SYN-010 on Subjects With IBS-C

NCT02495623 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Irritable Bowel Syndrome With Constipation (IBS-C)

Interventions

DRUG: SYN-010 21 mg
DRUG: SYN-010 42 mg
DRUG: Placebo

Sponsor

Theriva Biologics, Inc.